Happy Friday! It may not be a white Christmas for everyone, but with parts of the U.S. receiving upwards of four feet of snow last week, it's close enough. Speaking…
According to an NBC AP news item, early results show that CRISPR, a “tool” that alters DNA permanently in blood cells, has the potential to not only stop the progression…
Since its conception, biopharmaceutical company Geron Corporation ("Geron") has worked to develop first-in-class therapies for hematologic myeloid malignancies. More recently, Geron began evaluating imetelstat for patients with lower risk myelodysplastic syndromes…
In early December 2020, biopharmaceutical company Gilead Sciences, Inc. ("Gilead") shared updated results from a Phase 1b clinical trial evaluating magrolimab for patients with treatment-naïve acute myeloid leukemia (AML). Generally,…
by Lauren Taylor from In The Cloud Copy Pantothenate kinase-associated neurodegeneration or PKAN is a rare, inherited condition in which the affected child experiences progressive degeneration in certain parts of…
Overall, Galapagos works to develop small-molecule treatments for patients with a variety of conditions. In a recent press release, the company reported positive top-line data from the Phase 2 PINTA…
Axcella is a biotechnology company that has developed a new system of treating complex diseases. Its lead candidates are products that treat two liver diseases, as well as NASH, which…
For the entirety of 2020, our lives have been dominated by COVID-19, the novel coronavirus linked to 64.5 million cases and 1.49 million deaths across the globe. In the United…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
